The CEO and cofounder at Advanced Brain Monitoring talked about a study presented at AAIC 2024 that explored the use of EEG biomarkers to differentiate between Alzheimer disease and frontotemporal dementia.
Chris Berka
Advertisement
CEO and cofounder at Advanced Brain Monitoring.
Articles by Chris Berka
The CEO and cofounder at Advanced Brain Monitoring talked about how the early diagnosis of frontotemporal dementia is often mistaken for Alzheimer disease, but advancements in neuropsychological assessments and biomarker identification may improve accuracy. [WATCH TIME: 4 minutes]
The CEO and cofounder at Advanced Brain Monitoring discussed using EEG-based biomarkers to identify early markers that predict cognitive decline and aid in differential diagnosis for neurodegenerative diseases. [WATCH TIME: 4 minutes]
The CEO and cofounder at Advanced Brain Monitoring talked about how exploring electroencephalography patterns can help differentiate between Alzheimer disease, Lewy body dementia, and frontotemporal dementia. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
NeurologyLive® Friday 5 — October 17, 2025
4
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
5
